Skp2, p27kip1 and EGFR assessment in head and neck squamous cell carcinoma: Prognostic implications

Oncology Reports

Volumn 20, Issue 3, 2008, Pages 589-595

  Carracedo, Dario G ^a   Astudillo, Aurora ^a,b   Rodrigo, Juan P ^a,b   Suarez, Carlos ^a,b   Gonzalez, Maria Victoria ^a,c  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Hospital Nuestra Senora de Covadonga   (Spain)

Author keywords

Head and neck squamous cell carcinoma; P27kip1; Prognosis; Skp2

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR MARKER; VASCULOTROPIN RECEPTOR; CDKN1B PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; S PHASE KINASE ASSOCIATED PROTEIN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DOWN REGULATION; DYSPLASIA; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STAINING; WESTERN BLOTTING; APHASIA; CANCER STAGING; CELL NUCLEUS; CYTOPLASM; ENZYME IMMUNOASSAY; EPITHELIUM; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; LARYNX TUMOR; METABOLISM; MIDDLE AGED; OROPHARYNX TUMOR; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

APHASIA; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 54549121502     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Stewart BW and Kleihues, P: World Cancer Report Geneva: International Agency for Research on Cancer, 2003.
2. Perez-Ordonez B, Beauchemin M and Jordan RC: Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 59: 445-453, 2006.
3. Sherr CJ: Cell cycle control and cancer. Harvey Lect 96: 73-92, 2000.
4. Porter PL, Malone KE, Heagerty PJ, et al: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997.
5. Psyrri A, Bamias A, Yu Z, et al: Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 11: 8384-8390, 2005.
6. Masciullo V, Susini T, Zamparelli A, et al: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related endometrial adenocarcinomas. Clin Cancer Res 9: 5332-5338, 2003.
7. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K and Akiyoshi T: p27 expression and gastric carcinoma. Nat Med 3: 593, 1997.
8. Manne U, Jhala NC, Jones J, et al: Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage. Clin Cancer Res 10: 1743-1752, 2004.
9. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D and Lieskovosky G: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90: 916-920, 1998.
10. Esposito V, Baldi A, De Luca A, et al: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997.
11. Kudo Y, Kitajima S, Ogawa I, Miyauchi M and Takata T: Down-regulation of Cdk inhibitor p27 in oral squamous cell carcinoma. Oral Oncol 41: 105-116, 2005.
12. Bloom J and Pagano M: Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 13: 41-47, 2003.
13. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H and Sun H: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 11: 263-267, 2001.
14. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J and Krek W: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 98: 5043-5048, 2001.
15. Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz MM and Hershko A: Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91: 1745-1751, 2001.
16. Liang J, Zubovitz J, Petrocelli T, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160, 2002.
17. Viglietto G, Motti ML, Bruni P, et al: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/ Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136-1144, 2002.
18. Schmidt M, Fernandez de Mattos S, van der Horst A, et al: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842-7852, 2002.
19. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS and Gonzalez MV: Frequent genetic and bioche-mical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114: 242-248, 2005.
20. Sobin LH and Wittekind, C: TNM classification of malignant tumors. UICC. 6th edition, Wiley-Liss, New York, 2002.
21. Blain SW, Scher HI, Cordon-Cardo C and Koff A: p27 as a target for cancer therapeutics. Cancer Cell 3: 111-115, 2003.
22. Motti ML, Califano D, Troncone G, et al: Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 166: 737-749, 2005.
23. Rosen DG, Yang G, Cai KQ, Bast RC Jr, Gershenson DM, Silva EG and Liu J: Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11: 632-637, 2005.
24. Brandts CH, Bilanges B, Hare G, McCormick F and Stokoe D: Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells. J Biol Chem 280: 2012-2019, 2005.
25. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I and Takata T: High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 61: 7044-7047, 2001.
26. Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK and Perez-Soler R: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regu-lation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72: 248-258, 2007.
27. Ongkeko WM, Altuna X, Weisman RA and Wang-Rodriguez J: Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124: 71-76, 2005.
28. Khademi B, Shirazi FM, Vasei M, et al: The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184: 223-230, 2002.
29. Di Gennaro E, Barbarino M, Bruzzese F, et al: Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195: 139-150, 2003.